Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
13.00
+0.34 (2.69%)
Aug 13, 2025, 4:00 PM - Market closed

Company Description

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.

The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD).

The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications.

It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers.

The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011.

Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Adaptive Biotechnologies Corporation
Adaptive Biotechnologies logo
CountryUnited States
Founded2009
IPO DateJun 27, 2019
IndustryBiotechnology
SectorHealthcare
Employees619
CEOChad Robins

Contact Details

Address:
1165 Eastlake Avenue East
Seattle, Washington 98109
United States
Phone206 659 0067
Websiteadaptivebiotech.com

Stock Details

Ticker SymbolADPT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$20.00
CIK Code0001478320
CUSIP Number00650F109
ISIN NumberUS00650F1093
Employer ID27-0907024
SIC Code2836

Key Executives

NamePosition
Chad M. Robins M.B.A.Co-Founder, Chief Executive Officer and Chairman
Julie RubinsteinPresident and Chief Operating Officer
Dr. Harlan S. Robins Ph.D.Co-Founder and Chief Scientific Officer
Kyle PiskelVice President, Chief Financial Officer and Principal Accounting Officer
Dr. Sharon Benzeno Ph.D.Chief Commercial Officer of Immune Medicine
Christopher Carlson Ph.D.Founder
Karina CalzadillaVice President of Investor Relations
Clarice McCauleyInterim General Counsel, Corporate Secretary, Vice President and Chief Compliance Officer
Francis T. LoChief People Officer
Susan BobulskyChief Commercial Officer of MRD

Latest SEC Filings

DateTypeTitle
Aug 5, 202510-QQuarterly Report
Aug 5, 20258-KCurrent Report
Jul 9, 2025SCHEDULE 13G/AFiling
Jun 12, 20258-KCurrent Report
Jun 6, 2025SCHEDULE 13G/AFiling
May 14, 2025SCHEDULE 13GFiling
May 7, 2025SCHEDULE 13G/AFiling
May 1, 2025144Filing
May 1, 202510-QQuarterly Report
May 1, 20258-KCurrent Report